Advances in bioengineered CAR T/ NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/ NK cell therapy
Bioengineering & Translational Medicine · 2025-03 · 10 (2)
DOI: 10.1002/btm2.10716 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering & Translational Medicine, online erschienen am 31.08.2024. Verfasst von Nasim Dana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Applied Physiology Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 223 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma is a strong challenge in the worldwide field of central nervous system malignancies. GBM's inherent heterogeneity, along with the formation of an immunosuppressive tumor microenvironment, supports its resistance to current therapy methods. Immunotherapeutic methods have emerged as potential options in recent years. However, because of the inherent limits of traditional immunotherapeutic techniques innovative approaches are required. Advances in cut‐edge techniques provide a possible route for improving effector cell effectiveness. This review gives insight into the complicated immunosuppressive pathways in GBM, with a particular emphasis on CAR T/NK‐cell treatment as a potential achievement. Recognizing and addressing these concerns might open the way for more effective and focused glioblastoma therapies, providing hope for the future with the aim of improved outcomes for patients. In addition, this review presents valuable insights into the integration of nanotechnology into CAR T/NK cell therapy for enhanced efficiency of these personalized gene therapy products.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied Physiology Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran.
- Department of Microbiology, Faculty of biological science and technology The University of Isfahan Isfahan Iran.
- Department of Biomaterials, Nanotechnology and Tissue Engineering, School of Advanced Technologies in Medicine Isfahan University of Medical Sciences Isfahan Iran.
- Biosensor Research Center, School of Advanced Technologies in Medicine Isfahan University of Medical Sciences Isfahan Iran.
- Department of Otorhinolaryngology, The Dingli Clinical College affiliated to Wenzhou Medical University Wenzhou Central Hospital Wenzhou 325000 China.
- Institute of Polymers, Composites and Biomaterials National Research Council (IPCB-CNR) Naples Italy.
ORCID-Profile: Ilnaz Rahimmanesh, Pooyan Makvandi
Zitieren
APA
Dana, N., Dabiri, A., Najafi, M. B., Rahimi, A., Ishaghi, S. M. M., Shariati, L., Shao, M., Borzacchiello, A., Rahimmanesh, I., & Makvandi, P. (2025). Advances in bioengineered CAR T/ NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/ NK cell therapy. Bioengineering & Translational Medicine, 10(2). https://doi.org/10.1002/btm2.10716
Vancouver
Dana N, Dabiri A, Najafi MB, Rahimi A, Ishaghi SMM, Shariati L, et al. Advances in bioengineered CAR T/ NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/ NK cell therapy. Bioengineering & Translational Medicine. 2025;10(2). doi:10.1002/btm2.10716
BibTeX
@article{Dana2025,
author = {Dana, Nasim and Dabiri, Arezou and Najafi, Majed Bahri and Rahimi, Azadeh and Ishaghi, Sayed Mohammad Matin and Shariati, Laleh and Shao, Minmin and Borzacchiello, Assunta and Rahimmanesh, Ilnaz and Makvandi, Pooyan},
title = {Advances in bioengineered CAR T/ NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/ NK cell therapy},
journal = {Bioengineering & Translational Medicine},
year = {2025},
volume = {10},
number = {2},
doi = {10.1002/btm2.10716}
}
EUVIMED